{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:59:15Z","timestamp":1782975555452,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"DOI":"10.1007\/s00417-026-07360-8","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:26:35Z","timestamp":1782969995000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration"],"prefix":"10.1007","author":[{"given":"Noah Benjamin","family":"Nagar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ostrovsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nir","family":"Shoham-Hazon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raman","family":"Tuli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas Kin Man","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noy","family":"Buchnick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagiv","family":"Beluga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiza","family":"Bramnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilon","family":"Shcolnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalhevet","family":"Goldfeather Ben Zaken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niv","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mor","family":"Bareket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efraim","family":"Berco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"7360_CR1","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(18)31550-2","volume":"392","author":"P Mitchell","year":"2018","unstructured":"Mitchell P, Liew G, Gopinath B, Wong TY (2018) Age-related macular degeneration. Lancet 392:1147\u20131159. https:\/\/doi.org\/10.1016\/S0140-6736(18)31550-2","journal-title":"Lancet"},{"key":"7360_CR2","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1016\/j.ophtha.2024.12.018","volume":"132","author":"GA Vemulakonda","year":"2025","unstructured":"Vemulakonda GA, Bailey ST, Kim SJ et al (2025) Age-Related Macular Degeneration Preferred Practice Pattern\u00ae. Ophthalmology 132:P1\u2013P74. https:\/\/doi.org\/10.1016\/j.ophtha.2024.12.018","journal-title":"Ophthalmology"},{"key":"7360_CR3","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.oret.2024.01.004","volume":"8","author":"C Boudousq","year":"2024","unstructured":"Boudousq C, Nguyen V, Hunt A et al (2024) European Unmet Needs in the Management of Neovascular Age-Related Macular Degeneration in Daily Practice. Ophthalmol Retina 8:527\u2013536. https:\/\/doi.org\/10.1016\/j.oret.2024.01.004","journal-title":"Ophthalmol Retina"},{"key":"7360_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2147\/OPTH.S269162","volume":"15","author":"MR Cheema","year":"2021","unstructured":"Cheema MR, DaCosta J, Talks J (2021) Ten-Year Real-World Outcomes of Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration. Clin Ophthalmol Volume 15:279\u2013287. https:\/\/doi.org\/10.2147\/OPTH.S269162","journal-title":"Clin Ophthalmol Volume"},{"key":"7360_CR5","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.2147\/OPTH.S185052","volume":"12","author":"K Spooner","year":"2018","unstructured":"Spooner K, Mhlanga C, Hong T et al (2018) The burden of neovascular age-related macular degeneration: a patient\u2019s perspective. Clin Ophthalmol 12:2483\u20132491. https:\/\/doi.org\/10.2147\/OPTH.S185052","journal-title":"Clin Ophthalmol"},{"key":"7360_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502747","volume":"243","author":"J Mon\u00e9s","year":"2020","unstructured":"Mon\u00e9s J, Singh RP, Bandello F et al (2020) Undertreatment of Neovascular Age-Related Macular Degeneration after 10 Years of Anti-Vascular Endothelial Growth Factor Therapy in the Real World: The Need for A Change of Mindset. Ophthalmologica 243:1\u20138. https:\/\/doi.org\/10.1159\/000502747","journal-title":"Ophthalmologica"},{"key":"7360_CR7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/s41433-024-03370-0","volume":"39","author":"KYC Teo","year":"2025","unstructured":"Teo KYC, Eldem B, Joussen A et al (2025) Treatment regimens for optimising outcomes in patients with neovascular age-related macular degeneration. Eye 39:860\u2013869. https:\/\/doi.org\/10.1038\/s41433-024-03370-0","journal-title":"Eye"},{"key":"7360_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/IAE.0000000000003003","volume":"41","author":"JS Heier","year":"2021","unstructured":"Heier JS, Singh RP, Wykoff CC et al (2021) The angiopoietin\/Tie pathway in retinal vascular diseases: A review. Retina 41:1\u201319. https:\/\/doi.org\/10.1097\/IAE.0000000000003003","journal-title":"Retina"},{"key":"7360_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S0140-6736(22)00010-1","volume":"399","author":"JS Heier","year":"2022","unstructured":"Heier JS, Khanani AM, Quezada Ruiz C et al (2022) Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet 399:729\u2013740. https:\/\/doi.org\/10.1016\/S0140-6736(22)00010-1","journal-title":"Lancet"},{"key":"7360_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03943-7","author":"E Jin","year":"2025","unstructured":"Jin E, Chan AC, Thomas GN (2025) Efficacy of faricimab secondary to anti-vascular endothelial growth factor agents in patients with neovascular age-related macular degeneration: a systematic review and meta-analysis. Eye. https:\/\/doi.org\/10.1038\/s41433-025-03943-7","journal-title":"Eye"},{"key":"7360_CR11","doi-asserted-by":"publisher","first-page":"102915","DOI":"10.1016\/j.eclinm.2024.102915","volume":"78","author":"BE Wilson","year":"2024","unstructured":"Wilson BE, Booth CM (2024) Real-world data: bridging the gap between clinical trials and practice. eClinicalMedicine 78:102915. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102915","journal-title":"eClinicalMedicine"},{"key":"7360_CR12","doi-asserted-by":"publisher","first-page":"100069","DOI":"10.1016\/j.apjo.2024.100069","volume":"13","author":"SJ Woo","year":"2024","unstructured":"Woo SJ, Jung JA, Kim T et al (2024) Association of baseline factors with 1-year outcomes in the SB11-ranibizumab equivalence trial: A post hoc analysis. Asia-Pac J Ophthalmol 13:100069. https:\/\/doi.org\/10.1016\/j.apjo.2024.100069","journal-title":"Asia-Pac J Ophthalmol"},{"key":"7360_CR13","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","volume":"131","author":"AM Khanani","year":"2024","unstructured":"Khanani AM, Kotecha A, Chang A et al (2024) TENAYA and LUCERNE. Ophthalmology 131:914\u2013926. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.014","journal-title":"Ophthalmology"},{"key":"7360_CR14","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1038\/s41433-023-02553-5","volume":"37","author":"AM Khanani","year":"2023","unstructured":"Khanani AM, Aziz AA, Khan H et al (2023) The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study \u2013 6 month results. Eye 37:3574\u20133581. https:\/\/doi.org\/10.1038\/s41433-023-02553-5","journal-title":"Eye"},{"key":"7360_CR15","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.2147\/OPTH.S482948","volume":"18","author":"B Kunzmann","year":"2024","unstructured":"Kunzmann B, Schweig A, Bartz-Schmidt K, Sobolewska B (2024) Real-World-Data of Treatment-Na\u00efve and Previously Treated Patients Receiving Up to 3 Injections of Faricimab in Neovascular Age-Related Macular Degeneration. Clin Ophthalmol Volume 18:4029\u20134039. https:\/\/doi.org\/10.2147\/OPTH.S482948","journal-title":"Clin Ophthalmol Volume"},{"key":"7360_CR16","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1038\/s41433-022-02153-9","volume":"36","author":"U Chakravarthy","year":"2022","unstructured":"Chakravarthy U, Armendariz BG, Fauser S (2022) 15 years of anti-VEGF treatment for nAMD: success or failure or something in between? Eye 36:2232\u20132233. https:\/\/doi.org\/10.1038\/s41433-022-02153-9","journal-title":"Eye"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07360-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-026-07360-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-026-07360-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T05:26:35Z","timestamp":1782969995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-026-07360-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":16,"alternative-id":["7360"],"URL":"https:\/\/doi.org\/10.1007\/s00417-026-07360-8","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"10 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The Authors have no proprietary or commercial interest in any of the materials discussed in this article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Proprietary statement"}},{"value":"This article was previously submitted to\n                      Ophthalmologica\n                      and rejected on November 26, 2025.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Prior submission"}},{"value":"The authors declare no competing interests.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}